A Study of Web-Based Music Therapy for Adults with Drug-Resistant Epilepsy Using NeuroPace RNS Device Evaluating Effects of Daily Self-Administered Music on Seizure Activity and Quality of Life

What this Trial Is About

Researchers are evaluating the effect of daily self-administered musical stimuli on patients with drug-resistant epilepsy who have an implanted NeuroPace Responsive Neurostimulator RNS device. This study is a prospective, placebo-controlled, double-blinded randomized trial conducted in a natural home environment. It builds on prior studies that showed certain music may reduce epileptiform discharges and seizures in these patients. The trial aims to see if listening to specific music can lower epileptic activity and improve mood, quality of life, and cognition. Participants will be randomly assigned to one of three groups listening to an experimental musical piece Music A shown to positively affect epileptic activity, an active comparator piece similar but without known benefits Music B, or a preferred music excerpt with some modifications Music C. Each participant will listen daily to their assigned music on their personal device at a convenient time during the study period. Participants will be monitored over about 4 12 months with assessments at baseline, weeks 3-4, 9-10, and 13-14. Continuous brain activity data from the RNS device will measure epileptic episodes. Self-reported mood, quality of life, cognition, seizure frequency, and music preferences will be collected throughout the study. The team will also assess the feasibility of this at-home, self-administered auditory intervention. The overall study duration including retrospective data collection is approximately 5 12 months.

Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application